Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. (Nasdaq: SSII) files reports and disclosures with the U.S. Securities and Exchange Commission as a registrant with common stock listed on The Nasdaq Stock Market LLC. These SEC filings provide detailed information about the company’s operations in surgical robotics, including its SSi Mantra surgical robotic system and SSi Mudra surgical instruments.
On this page, you can review SSII’s periodic and current reports, such as Form 10-Q quarterly reports and Form 8-K current reports. In its filings and related press releases, SS Innovations has discussed revenue from system sales, instrument sales, warranty sales, and lease income, as well as information about installations of the SSi Mantra system and the cumulative number of surgeries performed. Filings also reference clinical and regulatory milestones, including a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and plans for a 510(k) premarket notification to the U.S. Food and Drug Administration.
SS Innovations’ Form 8-K filings frequently incorporate press releases as exhibits, covering topics such as financial results, telesurgery achievements using the SSi Mantra and the SSi Mantra Tele Surgeon Console, executive appointments, and participation in investor conferences. These documents also confirm that the company’s common stock trades under the symbol SSII and that it is incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
Stock Titan’s SEC filings page for SSII is designed to surface these regulatory documents alongside AI-powered summaries that explain key points in plain language. Users can quickly scan new 8-Ks, 10-Qs, and other filings, and identify disclosures related to revenue composition, operating performance, regulatory progress for the SSi Mantra system, and other material events affecting SS Innovations International Inc.
SS Innovations International, Inc. appointed Naveen Kumar Amar as its new Chief Financial Officer, effective September 24, 2025. The change was disclosed in a current report and accompanied by a press release and a formal employment agreement.
Mr. Amar, age 49, brings over 27 years of global corporate finance experience across accounting, audits, capital raising, compliance, taxation, mergers and acquisitions and investor relations. His background includes senior roles at SpiceExpress (the cargo unit of SpiceJet Ltd.), Munchado India, MSD Wellcome Trust Hilleman Laboratories, EDirect Proprietary Ltd. and GE India, and he is both a Chartered Accountant and Company Secretary in India.
The Company and Mr. Amar entered into a five-year employment agreement that provides for a base annual salary of approximately US$163,000, based on current Indian rupee to U.S. dollar exchange rates, and includes customary confidentiality, intellectual property, non-competition and non-solicitation provisions.
SS Innovations International, Inc. reported that the world’s first pediatric pyeloplasty telesurgery was successfully performed using its SSi Mantra surgical robotic system. This means a complex kidney-related procedure in a child was carried out remotely with the help of the company’s robot-assisted platform, highlighting a significant technical and clinical milestone for its technology. The company furnished a press release with additional details as an exhibit to this report.
SS Innovations International, Inc. reported a technology milestone, disclosing that it successfully completed the first robotic telesurgery performed from its bus mobile robotic telesurgery unit. This procedure was announced in a company press release and highlights the use of its robotic system in a mobile, remote-surgery setting. The press release describing the event is filed as an exhibit to the report.
Insider transactions reported for SS Innovations International, Inc. (SSII) by Sudhir Srivastava, Chairman and CEO. The filing shows two non-derivative transactions in early September 2025: on 09/03/2025 Mr. Srivastava was reported as acquiring 2,500 shares, and on 09/05/2025 he was reported as disposing of 105,000 shares. After these transactions, the total shares beneficially owned attributable to Mr. Srivastava through Sushruta Pvt. Ltd. is reported as 112,583,014 shares. The form states the holdings are indirect because the reporting person has a controlling interest in Sushruta Pvt. Ltd.
Sudhir Srivastava, identified as a Director, 10% owner and the company's Chairman and CEO, reported a series of non-derivative transactions in the common stock of SS Innovations International, Inc. (SSII) executed through an entity he controls, Sushruta Pvt. Ltd. The Form 4 shows multiple acquisitions and dispositions between 05/12/2025 and 08/11/2025, including total reported acquisitions of 60,000 shares and total reported dispositions of 111,000 shares. After the last reported transaction the beneficial ownership held indirectly by Sushruta Pvt. Ltd. is shown as 112,685,514 common shares. Table II (derivative securities) contains no entries. The filing includes an explanatory note that the reporting person has a controlling interest in Sushruta Pvt. Ltd., which holds the securities of record.
What happened: SS Innovations reported strong sales growth this quarter and in the first half of 2025, driven by system and instrument sales. Total revenue for the quarter was $10.0M and for the first six months $15.1M. Gross profit rose and operating results improved to a small positive operating income for the quarter, and the company completed an uplisting to NASDAQ.
Why it matters: The company boosted cash to $17.6M after financings and conversions, which helps near-term operations, but it still reported a $5.94M net loss for the first half and a small quarterly net loss after tax. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes dependence on related-party financing and convertible note conversions.
SS Innovations International, Inc. (Nasdaq: SSII) filed a Form 8-K dated 15 July 2025 to disclose an operational milestone. The company reports that it has now installed more than 100 SSi Mantra surgical robotic systems across India and six other countries. Collectively, the installed base has facilitated over 5,000 surgical procedures, including 240 cardiac surgeries and 32 telesurgeries.
The filing contains no revenue, earnings, guidance or transactional information; it simply furnishes the related press release as Exhibit 99.1. While financial details are absent, the figures provided highlight growing clinical adoption and an expanding geographic presence for the Mantra platform.